Human BID Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-Human BID antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityHuman BID
Clonepolyclonal
Host SpeciesGoat
Reactive SpeciesGibbon, gorilla, human, orangutan
Isotypen/a
Formatimmunoaffinity purified
Size0.05 mg
Concentration0.5 mg/ml
ApplicationsImmunohistochemistry (IHC - Paraffin), Western Blot (WB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionSpecificity: Human BID. This antibody is expected to recognise all three reported isoforms (as represented by NP_932070.1; NP_001187.1; NP_932071.1). Apoptosis plays a major role in normal organism development, tissue homeostasis, and removal of damaged cells. Disruption of this process has been implicated in a variety of diseases such as cancer. The Bcl-2 family of proteins is comprised of critical regulators of apoptosis that can be divided into two classes: those that inhibit apoptosis and those that promote cell death.
ImmunogenImmunogen Description: Synthetic peptide C-TYVRSLARNGMD from the C-terminus of human BID (NP_932070.1; NP_001187.1; NP_932071.1). Percent identity by BLAST analysis: Human, Gorilla, Orangutan, Gibbon (100%); Monkey (92%).
Other Names[BID (C-Terminus) IHC-plus; BID; Apoptic death agonist; BID isoform L(2); BID isoform Si6; Bh3; FP497; p22 BID; BID isoform ES(1b); Desmocollin type 4; Human BID coding sequence; Human BID], [BID; BID; FP497; BID]
Gene, Accession #[BID], Gene ID: 637, NCBI: NP_001187.1, UniProt: P55957
Catalog #MBS248705
Price$530
Order / More InfoHuman BID Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.